GB/T 48011-2026 具有组织密度差的可吸收生物材料 体内降解率测定 X射线显微CT法
GB/T 48011-2026 Absorbable/resorbable biomaterials characterized by different density from surrounding tissue—Determination of the biodegradation in vivo—X-ray microCT test method
基本信息
本文件适用于可吸收生物材料体内降解率的测定。
本文件不适用于与植入物周围组织无密度差异，或由于金属伪影严重而不符合显微CT检测范围的可吸收生物材料的体内降解率测定。
注：与植入物周围组织无密度差异，或由于金属伪影严重而不符合显微CT检测范围的可吸收生物材料的体内降解率测定方法见GB/T 16886.6。
发布历史
-
2026年07月
文前页预览
研制信息
- 起草单位：
- 北京大学口腔医院、山东省医疗器械和药品包装检验研究院、山东隽秀生物科技股份有限公司、江苏创健医疗科技股份有限公司、四川大学、深圳市药品检验研究院(深圳市医疗器械检测中心)、北京邦塞科技有限公司、北京纳通医学研究院有限公司、北京莱顿生物材料有限公司、中科辰兴(北京)生物医药科技有限公司
- 起草人：
- 周永胜、刘浩、朱福余、高秀岩、钱松、李雪峰、林柏佑、杨孔艳、曹晓艳、夏宇、刘强、刘云松、白玉龙、袁暾、聂洪涛、任孝敏、吕珑薇、张晓、刘增祥、张博
- 出版信息：
- 页数：16页 | 字数：21 千字 | 开本： 大16开
内容描述
ICS11.100.20
CCSC30
中华人民共和国国家标准
GB/T48011—2026
具有组织密度差的可吸收生物材料
体内降解率测定X射线显微CT法
Absorbable/resorbablebiomaterialscharacterizedbydifferentdensity
fromsurroundingtissue—Determinationofthebiodegradationinvivo—
X⁃raymicroCTtestmethod
2026⁃07⁃02发布2027⁃08⁃01实施
国家市场监督管理总局
发布
国家标准化管理委员会
GB/T48011—2026
目次
前言··························································································································Ⅲ
引言··························································································································Ⅳ
1范围·······················································································································1
2规范性引用文件········································································································1
3术语和定义··············································································································1
4原理·······················································································································2
5试验条件·················································································································2
5.1显微CT机房要求·······························································································2
5.2检测人员要求·····································································································2
6仪器设备·················································································································2
6.1设备组成···········································································································2
6.2X射线显微CT设备·····························································································2
6.3图像处理系统·····································································································3
7实验动物·················································································································3
8试验样品·················································································································3
8.1离体样品···········································································································3
8.2活体样品···········································································································3
9试验步骤·················································································································3
9.1设备准备与校验··································································································3
9.2系统自检与探测器校正·························································································4
9.3标本放置···········································································································4
9.4设定扫描参数·····································································································4
9.5扫描图像矩阵·····································································································4
9.6采样时间···········································································································5
9.7扫描测试···········································································································5
9.8图像重建···········································································································5
9.9试验模型举例·····································································································5
10结果观察及试验数据处理··························································································5
10.1材料降解的定性分析···························································································5
10.2材料降解的定量分析···························································································5
11试验报告···············································································································6
附录A（资料性）口腔填充用骨粉体内降解情况的显微CT检测方法·······································7
A.1概述·················································································································7
Ⅰ
GB/T48011—2026
A.2显微CT扫描和数据重建······················································································7
A.3口腔填充用骨粉体内降解情况的定性评估·································································7
A.4口腔填充用骨粉体内降解情况的定量评估·································································8
参考文献·····················································································································9
Ⅱ
GB/T48011—2026
前言
本文件按照GB/T1.1—2020《标准化工作导则第1部分：标准化文件的结构和起草规则》的规定
起草。
请注意本文件的某些内容可能涉及专利。本文件的发布机构不承担识别专利的责任。
本文件由国家药品监督管理局提出。
本文件由全国医疗器械生物学评价标准化技术委员会（SAC/TC248）归口。
本文件起草单位：北京大学口腔医院、山东省医疗器械和药品包装检验研究院、山东隽秀生物科技
股份有限公司、江苏创健医疗科技股份有限公司、四川大学、深圳市药品检验研究院（深圳市医疗器械
检测中心）、北京邦塞科技有限公司、北京纳通医学研究院有限公司、北京莱顿生物材料有限公司、中科
辰兴（北京）生物医药科技有限公司。
本文件主要起草人：周永胜、刘浩、朱福余、高秀岩、钱松、李雪峰、林柏佑、杨孔艳、曹晓艳、夏宇、
刘强、刘云松、白玉龙、袁暾、聂洪涛、任孝敏、吕珑薇、张晓、刘增祥、张博。
Ⅲ
GB/T48011—2026
引言
目前，评价材料降解性能的方式主要有体外和体内两种。体外降解虽能在一定程度上反映材料在
模拟体液中的降解行为，但无法真实地反映在体效果。而在体内降解试验中，研究者通常通过处死实
验动物后进行植入物称重、测量和组织病理染色测面积等方式，观察材料在体内的降解行为。然而，材
料降解前后体积的变化对评价材料降解性能也很重要，而称重只能通过质量变化间接反映体积变化。
此外，体内降解后的材料混杂了大量机体组织（如新生骨、结缔组织等），难以精确评估材料的质量变
化；某些生物可吸收材料外观不规则，通过测量仅能粗略判断其体积变化。尽管通过组织切片染色能
精确测量特定材料断层的面积，但由于切片过程中存在组织损耗问题，将所有生物可吸收材料的断层
面积进行汇总计算存在挑战，通常只能通过分析特定几层切片的面积来估算其体积。此外，该方法既
耗时又费力，且对组织具有一定的破坏性。
显微CT又称微型CT，是一种非破坏性的3D成像技术，能够在不破坏样本在体状态的情况下，
清楚了解样本的内部显微结构。它与普通临床CT最大的区别在于其分辨率极高，可达到微米（μm）
级别，能够清晰地分辨出具有密度差异的细微成分。配合仪器的分析软件，显微CT可实现对材料体
积、粒径、数量、分离度等数据的无损精确观测。
Ⅳ
GB/T48011—2026
具有组织密度差的可吸收生物材料
体内降解率测定X射线显微CT法
1范围
本文件规定了具有组织密度差的可吸收生物材料（简称“可吸收生物材料”）在体内降解过程中使
用X射线显微CT测定体内降解率的方法，以及体内降解情况的分析方法。
本文件适用于可吸收生物材料体内降解率的测定。
本文件不适用于与植入物周围组织无密度差异，或由于金属伪影严重而不符合显微CT检测范围
的可吸收生物材料的体内降解率测定。
注：与植入物周围组织无密度差异，或由于金属伪影严重而不符合显微CT检测范围的可吸收生物材料的体内降解
率测定方法见GB/T16886.6。
2规范性引用文件
下列文件中的内容通过文中的规范性引用而构成本文件必不可少的条款。其中，注日期的引用文
件，仅该日期对应的版本适用于本文件；不注日期的引用文件，其最新版本（包括所有的修改单）适用于
本文件。
GB/T9445无损检测人员资格鉴定与认证
GB/T16886.6医疗器械生物学评价第6部分：植入后局部反应试验
GB/T23901.1无损检测射线照相检测图像质量第1部分：丝型像质计像质值的测定
GB/T23901.5无损检测射线照相检测图像质量第5部分：双丝型像质计图像不清晰度的
测定
GB/T29034无损检测工业计算机层析成像（CT）指南
GB/T29070无损检测工业计算机层析成像（CT）检测通用要求
NB/T47013.11承压设备无损检测第11部分：射线数字成像检测
3术语和定义
下列术语和定义适用于本文件。
3.1
X射线显微CT检测X⁃raymicroCTtesting
通过X射线束，在对检测物体无损伤条件下，以二维断层图像或三维立体图像的形式，高清、准确、
直观地展示被检测物体的内部细微结构、组成及缺损状况的技术。
3.2
组织密度tissuedensity
生物体组织单位体积内所含的质量。
注1：在CT影像学领域，组织密度用HounsfieldUnit（HU）表示。
注2：通常，相邻组织密度差>500HU被认为是具有组织密度差。
注3：具有组织密度差的可吸收生物材料通常涉及高分子材料、金属与合金材料、无机非金属材料、复合材料等，如
可吸收骨板、骨钉、生物膜、骨粉、血管支架、缝线等。通过预实验评估植入物周围组织与可吸收生物材料之间
难以判定的密度差异。
1
定制服务
推荐标准
- DB65/T 3756-2015 有机产品 日光温室哈密瓜生产技术规程 2015-09-30
- DB12/ 588-2015 在用非道路柴油机械烟度排放限值及测量方法 2015-06-29
- DB65/T 3770-2015 生态健康果品 库尔勒香梨 2015-08-10
- DB65/T 3780-2015 地理标志产品 吐鲁番葡萄酒 2015-09-15
- DB12/T 590-2015 在用汽车排气污染物限值及检测方法（遥测法） 2015-06-29
- DB12/ 589-2015 在用点燃式发动机轻型汽车排气污染物排放限值及测量方法（稳态工况法） 2015-06-29
- DB46/T 360-2016 住宅小区公共信息标志设置规范 2016-01-19
- DB65/T 3783-2015 绿色食品 树莓病虫害防治技术规程 2015-09-22
- DB31/T 925-2015 景区旅游休闲服务设施规划导则 2015-09-16
- DB31/T 636.2-2015 会议经营与服务规范 第2部分：会议场所服务机构 2015-09-16